Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 16/20 | 0.55 |
| ▸ | CCND1 | P24385 | 15/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.55 |
| ▸ | CCND3 | P30281 | 14/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.55 |
| ▸ | CDK2 | P24941 | 13/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.55 |
| ▸ | CDK9 | P50750 | 10/20 | 0.55 |
| ▸ | CDK7 | P50613 | 9/20 | 0.55 |
| ▸ | CCNH | P51946 | 9/20 | 0.55 |
| ▸ | CDK1 | P06493 | 6/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24676793 | 0.76 | CDK2 (0.71) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL18481292 | 0.76 | CDK4 (0.46) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL18453974 | 0.76 | CDK4 (0.63) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL24676459 | 0.75 | CDK4 (0.45) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL30945405 | 0.74 | DYRK2 (0.57) | — | |
| SCHEMBL18481291 | 0.72 | CDK4 (0.69) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL20463052 | 0.72 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL24675986 | 0.71 | CDK2 (0.66) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL20463054 | 0.71 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CCNA2 | |
| SCHEMBL18453323 | 0.71 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| US-20250049796-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-02-13 | — | — | US | disclosed |
| EP-4504200-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | Aucentra Therapeutics Pty Ltd (AU) | 2025-02-12 | — | — | EP | disclosed |
| CN-118871112-A | Use of 4-thiazol-N- (pyridin-2-yl) pyrimidin-2-amine derivatives in cancer combination therapy | 澳升医药公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-04-30 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| WO-2023173170-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-09-21 | — | — | WO | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| US-20230181580-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-15 | — | — | US | disclosed |
| EP-4146201-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | Aucentra Therapeutics Pty Ltd (AU) | 2023-03-15 | — | — | EP | disclosed |
| EP-3957637-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Therapeutics Pty Ltd (AU) | 2022-02-23 | — | — | EP | disclosed |
| EP-3331880-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021222967-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-11-11 | — | — | WO | disclosed |
| CN-113336746-A | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108349964-B | N- (pyridin-2-yl) -4- (thiazol-5-yl) pyrimidin-2-amines as therapeutic compounds | 常州千红生化制药股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| EP-3331880-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | University Of South Australia (AU) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017020065-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181580-A1 | TREATMENT OF PROLIFERATIVE DISEASES OF THE CNS | CDK6, CDK4, CDK3 | CDK4 2/4885CCND1 47/4885CDK6 1/4885 |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | CDK4 1/4885CCND1 17/4885CDK6 2/4885 |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | CDK4 1/4885CCND1 14/4885CDK6 2/4885 |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK2 | CDK4 1/4885CCND1 17/4885CDK6 2/4885 |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDKL2 | CDK4 1/4885CCND1 17/4885CDK6 2/4885 |
| US-20250049796-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | CD274, PDCD1LG2, PDCD1 | CDK4 63/4885CCND1 2121/4885CDK6 359/4885 |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK3 | CDK4 1/4885CCND1 18/4885CDK6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.